miR‑638 suppresses proliferation by negatively regulating high mobility group A1 in ovarian cancer cells

Ma,Li; Zhang,Wei; Jin,Yaofeng; Bai,Xiaomei; Yu,Qiaoling

doi:10.3892/etm.2021.10754

miR‑638 suppresses proliferation by negatively regulating high mobility group A1 in ovarian cancer cells

Authors:
- Li Ma
- Wei Zhang
- Yaofeng Jin
- Xiaomei Bai
- Qiaoling Yu
View Affiliations

Affiliations: Department of Pathology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China, Department of Scientific Research, The First Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi 710077, P.R. China
Published online on: September 20, 2021 https://doi.org/10.3892/etm.2021.10754
Article Number: 1319
Copyright: © Ma et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer is one of the most common gynecological diseases with high mortality rates. Previous studies have shown that microRNA (miR)‑638 is associated with tumorigenesis. The present study aimed to assess the role and underlying mechanisms of miR‑638 in ovarian cancer. miR‑638 expression was detected in ovarian cancer tissues and miR‑638 was overexpressed or knocked down in ovarian cancer OVCAR‑3 and Caov‑3 cells. The clinical results revealed that miR‑638 expression was downregulated in ovarian cancer tissues compared with in adjacent normal tissues. miR‑638 expression was also found to be relatively low in OVCAR‑3 cells whilst being relatively high in Caov‑3 cells among the five ovarian cancer cell lines tested. miR‑638 overexpression inhibited cell viability, arrested the cell cycle at the G1 phase and promoted apoptosis in OVCAR‑3 cells. By contrast, miR‑638 knockdown increased Caov‑3 cell viability, facilitated cell cycle progression and inhibited apoptosis. miR‑638 reduced the expression of high mobility group A1 (HMGA1) by directly targeting its 3' untranslated region. HMGA1 overexpression reversed the inhibition of proliferation induced by miR‑638 overexpression in OVCAR‑3 cells. These results suggest that miR‑638 may serve to be a suppressor of ovarian cancer by regulating HMGA1, which may provide a potential therapeutic target for ovarian cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019.PubMed/NCBI View Article : Google Scholar
2	Webb PM and Jordan SJ: Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 41:3–14. 2017.PubMed/NCBI View Article : Google Scholar
3	Bonifácio VDB: Ovarian cancer biomarkers: Moving forward in early detection. Adv Exp Med Biol. 1219:355–363. 2020.PubMed/NCBI View Article : Google Scholar
4	Hennessy BT, Coleman RL and Markman M: Ovarian cancer. Lancet. 374:1371–1382. 2009.PubMed/NCBI View Article : Google Scholar
5	Doubeni CA, Doubeni AR and Myers AE: Diagnosis and management of ovarian cancer. Am Fam Physician. 93:937–944. 2016.PubMed/NCBI
6	Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, et al: Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 363:943–953. 2010.PubMed/NCBI View Article : Google Scholar
7	Visone R and Croce CM: miRNAs and cancer. Am J Pathol. 174:1131–1138. 2009.PubMed/NCBI View Article : Google Scholar
8	Li M, Wang J and Liu H: Downregulation of miR-638 promotes progression of breast cancer and is associated with prognosis of breast cancer patients. Onco Targets Ther. 11:6871–6877. 2018.PubMed/NCBI View Article : Google Scholar
9	Shen Y, Chen H, Gao L, Zhang W, He J, Yang X, Qin L, Xue X and Guo Z: miR-638 acts as a tumor suppressor gene in gastric cancer. Oncotarget. 8:108170–108180. 2017.PubMed/NCBI View Article : Google Scholar
10	Wei H, Zhang JJ and Tang QL: miR-638 inhibits cervical cancer metastasis through Wnt/β-catenin signaling pathway and correlates with prognosis of cervical cancer patients. Eur Rev Med Pharmacol Sci. 21:5587–5593. 2017.PubMed/NCBI View Article : Google Scholar
11	Bhattacharya A, Schmitz U, Raatz Y, Schönherr M, Kottek T, Schauer M, Franz S, Saalbach A, Anderegg U, Wolkenhauer O, et al: miR-638 promotes melanoma metastasis and protects melanoma cells from apoptosis and autophagy. Oncotarget. 6:2966–2980. 2015.PubMed/NCBI View Article : Google Scholar
12	Ren Y, Chen Y, Liang X, Lu Y, Pan W and Yang M: miRNA-638 promotes autophagy and malignant phenotypes of cancer cells via directly suppressing DACT3. Cancer Lett. 390:126–136. 2017.PubMed/NCBI View Article : Google Scholar
13	Lu X, Chen L, Chen Y, Shao Q and Qin W: Bafilomycin A1 inhibits the growth and metastatic potential of the BEL-7402 liver cancer and HO-8910 ovarian cancer cell lines and induces alterations in their microRNA expression. Exp Ther Med. 10:1829–1834. 2015.PubMed/NCBI View Article : Google Scholar
14	Penzo C, Arnoldo L, Pegoraro S, Petrosino S, Ros G, Zanin R, Wiśniewski JR, Manfioletti G and Sgarra R: HMGA1 modulates gene transcription sustaining a tumor signalling pathway acting on the epigenetic status of triple-negative breast cancer cells. Cancers (Basel). 11(1105)2019.PubMed/NCBI View Article : Google Scholar
15	Wang Y, Hu L, Zheng Y and Guo L: HMGA1 in cancer: Cancer classification by location. J Cell Mol Med. 23:2293–2302. 2019.PubMed/NCBI View Article : Google Scholar
16	Lund T, Holtlund J, Fredriksen M and Laland SG: On the presence of two new high mobility group-like proteins in HeLa S3 cells. FEBS Lett. 152:163–167. 1983.PubMed/NCBI View Article : Google Scholar
17	Méndez O, Pérez J, Soberino J, Racca F, Cortés J and Villanueva J: Clinical implications of extracellular HMGA1 in breast cancer. Int J Mol Sci. 20(5950)2019.PubMed/NCBI View Article : Google Scholar
18	Zanin R, Pegoraro S, Ros G, Ciani Y, Piazza S, Bossi F, Bulla R, Zennaro C, Tonon F, Lazarevic D, et al: HMGA1 promotes breast cancer angiogenesis supporting the stability, nuclear localization and transcriptional activity of FOXM1. J Exp Clin Cancer Res. 38(313)2019.PubMed/NCBI View Article : Google Scholar
19	Cao XP, Cao Y, Zhao H, Yin J and Hou P: HMGA1 promoting gastric cancer oncogenic and glycolytic phenotypes by regulating c-myc expression. Biochem Biophys Res Commun. 516:457–465. 2019.PubMed/NCBI View Article : Google Scholar
20	Jing Z, Liu C, Zhang QH, Chen L, Shen YY, Chen YJ, Zeng X, Zu XY and Cao RX: TGF-β1 induces HMGA1 expression: The role of HMGA1 in thyroid cancer proliferation and invasion. Int J Oncol. 50:1567–1578. 2017.PubMed/NCBI View Article : Google Scholar
21	Peters DG, Kudla DM, DeLoia JA, Chu TJ, Fairfull L, Edwards RP and Ferrell RE: Comparative gene expression analysis of ovarian carcinoma and normal ovarian epithelium by serial analysis of gene expression. Cancer Epidemiol Biomarkers Prev. 14:1717–1723. 2005.PubMed/NCBI View Article : Google Scholar
22	Liu Y, Wang Y, Zhang Y, Fu J and Zhang G: Knockdown of HMGA1 expression by short/small hairpin RNA inhibits growth of ovarian carcinoma cells. Biotechnol Appl Biochem. 59:1–5. 2012.PubMed/NCBI View Article : Google Scholar
23	Ma T, Zhao Z, Wang Z, Wang C and Zhang L: miR-940 inhibits migration and invasion of tongue squamous cell carcinoma via regulatingCXCR2/NF-κB system-mediated epithelial-mesenchymal transition. Naunyn Schmiedebergs Arch Pharmacol. 392:1359–1369. 2019.PubMed/NCBI View Article : Google Scholar
24	Schmittgen TD and Livak KJ: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
25	González-Magaña A and Blanco FJ: Human PCNA structure, function and interactions. Biomolecules. 10(570)2020.PubMed/NCBI View Article : Google Scholar
26	Heneghan HM, Miller N and Kerin MJ: miRNAs as biomarkers and therapeutic targets in cancer. Curr Opin Pharmacol. 10:543–550. 2010.PubMed/NCBI View Article : Google Scholar
27	Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et al: MicroRNA signatures in human ovarian cancer. Cancer Res. 67:8699–8707. 2007.PubMed/NCBI View Article : Google Scholar
28	Lu J, Wang L, Chen W, Wang Y, Zhen S, Chen H, Cheng J, Zhou Y, Li X and Zhao L: miR-603 targeted hexokinase-2 to inhibit the malignancy of ovarian cancer cells. Arch Biochem Biophys. 661:1–9. 2019.PubMed/NCBI View Article : Google Scholar
29	Creighton CJ, Fountain MD, Yu Z, Nagaraja AK, Zhu H, Khan M, Olokpa E, Zariff A, Gunaratne PH, Matzuk MM and Anderson ML: Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Cancer Res. 70:1906–1915. 2010.PubMed/NCBI View Article : Google Scholar
30	Chao A, Lin CY, Lee YS, Tsai CL, Wei PC, Hsueh S, Wu TI, Tsai CN, Wang CJ, Chao AS, et al: Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2. Oncogene. 31:764–775. 2012.PubMed/NCBI View Article : Google Scholar
31	Zhao W, Han T, Li B, Ma Q, Yang P and Li H: miR-552 promotes ovarian cancer progression by regulating PTEN pathway. J Ovarian Res. 12(121)2019.PubMed/NCBI View Article : Google Scholar
32	Di Leva G, Garofalo M and Croce CM: MicroRNAs in cancer. Annu Rev. 9:287–314. 2014.PubMed/NCBI View Article : Google Scholar
33	Zhao LY, Yao Y, Han J, Yang J, Wang XF, Tong DD, Song TS, Huang C and Shao Y: miR-638 suppresses cell proliferation in gastric cancer by targeting Sp2. Dig Dis Sci. 59:1743–1753. 2014.PubMed/NCBI View Article : Google Scholar
34	Cheng J, Chen Y, Zhao P, Liu X, Dong J, Li J, Huang C, Wu R and Lv Y: Downregulation of miRNA-638 promotes angiogenesis and growth of hepatocellular carcinoma by targeting VEGF. Oncotarget. 7:30702–30711. 2016.PubMed/NCBI View Article : Google Scholar
35	Juríková M, Danihel L', Polák Š and Varga I: Ki67, PCNA, and MCM proteins: Markers of proliferation in the diagnosis of breast cancer. Acta Histochem. 118:544–552. 2016.PubMed/NCBI View Article : Google Scholar
36	Zhao H, Ho PC, Lo YH, Espejo A, Bedford MT, Hung MC and Wang SC: Interaction of proliferation cell nuclear antigen (PCNA) with c-Abl in cell proliferation and response to DNA damages in breast cancer. PLoS One. 7(e29416)2012.PubMed/NCBI View Article : Google Scholar
37	Madhumati G, Kavita S, Anju M, Uma S and Raj M: Immunohistochemical expression of cell proliferating nuclear antigen (PCNA) and p53 protein in cervical cancer. J Obstet Gynecol India. 62:557–561. 2012.PubMed/NCBI View Article : Google Scholar
38	Xia B, Yang S, Liu T and Lou G: miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6. Mol Cancer. 14(57)2015.PubMed/NCBI View Article : Google Scholar
39	Khan S, Brougham CL, Ryan J, Sahrudin A, O'Neill G, Wall D, Curran C, Newell J, Kerin MJ and Dwyer RM: miR-379 regulates Cyclin B1 expression and is decreased in breast cancer. PLoS One. 8(e68753)2013.PubMed/NCBI View Article : Google Scholar
40	Radu A, Neubauer V, Akagi T, Hanafusa H and Georgescu MM: PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1. Mol Cell Biol. 23:6139–6149. 2003.PubMed/NCBI View Article : Google Scholar
41	He L, Zhu W, Chen Q, Yuan Y, Wang Y, Wang J and Wu X: Ovarian cancer cell-secreted exosomal miR-205 promotes metastasis by inducing angiogenesis. Theranostics. 9:8206–8220. 2019.PubMed/NCBI View Article : Google Scholar
42	Hong SJ, Dawson TM and Dawson VL: Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol Sci. 25:259–264. 2004.PubMed/NCBI View Article : Google Scholar
43	Porter AG and Janicke RU: Emerging roles of Caspase-3 in. Cell Death Differ. 6:99–104. 2015.
44	Zhang H, Li Y, Huang Q, Ren X, Hu H, Sheng H and Lai M: miR-148a promotes apoptosis by targeting Bcl-2 in colorectal cancer. Cell Death Differ. 18:1702–1710. 2011.PubMed/NCBI View Article : Google Scholar
45	Liu J, Tu F, Yao W, Li X, Xie Z, Liu H, Li Q and Pan Z: Conserved miR-26b enhances ovarian granulosa cell apoptosis through HAS2-HA-CD44-Caspase-3 pathway by targeting HAS2. Sci Rep. 6(21197)2016.PubMed/NCBI View Article : Google Scholar
46	Masciullo V, Baldassarre G, Pentimalli F, Berlingieri MT, Boccia A, Chiappetta G, Palazzo J, Manfioletti G, Giancotti V, Viglietto G, et al: HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas. Carcinogenesis. 24:1191–1198. 2003.PubMed/NCBI View Article : Google Scholar
47	Wei JJ, Wu X, Peng Y, Shi G, Basturk O, Yang X, Daniels G, Osman I, Ouyang J, Hernando E, et al: Regulation of HMGA1 expression by MicroRNA-296 affects prostate cancer growth and invasion. Clin Cancer Res. 17:1297–1305. 2011.PubMed/NCBI View Article : Google Scholar
48	Chen YN, Ren CC, Yang L, Nai MM, Xu YM, Zhang F and Liu Y: MicroRNA let-7d-5p rescues ovarian cancer cell apoptosis and restores chemosensitivity by regulating the p53 signaling pathway via HMGA1. Int J Oncol. 54:1771–1784. 2019.PubMed/NCBI View Article : Google Scholar